• LAST PRICE
    41.8800
  • TODAY'S CHANGE (%)
    Trending Down-0.4100 (-0.9695%)
  • Bid / Lots
    41.8000/ 2
  • Ask / Lots
    41.9600/ 2
  • Open / Previous Close
    42.6000 / 42.2900
  • Day Range
    Low 41.3900
    High 42.6400
  • 52 Week Range
    Low 26.6100
    High 75.0167
  • Volume
    379,500
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 42.29
TimeVolumeGPCR
09:32 ET194042.455
09:34 ET82042.53
09:36 ET2369542
09:38 ET30042.26
09:39 ET25042.0502
09:41 ET185042.5
09:43 ET154842.385
09:45 ET50042.3836
09:48 ET125042.55
09:52 ET103242.5
09:54 ET10042.505
09:56 ET10042.495
09:59 ET110042.485
10:03 ET10042.61
10:08 ET10042.485
10:14 ET35042.501568
10:15 ET10042.475
10:17 ET40042.475
10:21 ET137542.39
10:24 ET375842.145
10:26 ET498741.87
10:28 ET35042.0699
10:32 ET40041.955
10:33 ET72042
10:35 ET50041.98
10:37 ET40641.87
10:39 ET70041.94
10:42 ET170041.965
10:44 ET70042
10:46 ET20041.99
10:48 ET61542
10:50 ET130041.88
10:51 ET350042.085
10:53 ET50042.13
10:55 ET100042.13
10:57 ET35042.0201
11:00 ET50042.05
11:02 ET20042.13
11:04 ET10042.13
11:06 ET211241.99
11:08 ET40042.015
11:09 ET100742.035
11:11 ET20042.035
11:13 ET120041.7
11:15 ET69941.72
11:18 ET190041.6401
11:20 ET10041.785
11:22 ET10041.74
11:24 ET163841.8
11:26 ET50441.775
11:27 ET23541.78
11:29 ET195441.66
11:31 ET38441.55
11:33 ET10041.62
11:36 ET30041.6
11:40 ET30041.57
11:42 ET422441.5365
11:44 ET40041.67
11:45 ET20041.665
11:47 ET20041.715
11:49 ET57941.7206
11:54 ET20041.715
11:56 ET170041.68
11:58 ET121941.6521
12:00 ET60041.74
12:02 ET20141.82
12:05 ET25041.92
12:07 ET10041.91
12:09 ET20041.94
12:12 ET130042.005
12:16 ET31942.01
12:18 ET125042.04
12:20 ET20042.04
12:23 ET316542.3
12:25 ET70042.205
12:30 ET25042.245
12:32 ET16891442.025
12:34 ET35042.115
12:36 ET10042.125
12:38 ET35042.25
12:39 ET1201042.13
12:41 ET103542.11
12:43 ET10042.165
12:45 ET398642.25
12:48 ET170042.25
12:50 ET240042.1
12:52 ET10042.16
12:56 ET593442
12:59 ET49042
01:01 ET218542.09
01:03 ET72142.2023
01:06 ET10042.205
01:10 ET10042.145
01:12 ET573342.18
01:14 ET410942.22
01:15 ET672142.56
01:17 ET60042.6
01:19 ET50042.64
01:21 ET25042.5941
01:24 ET10042.585
01:26 ET10042.63
01:28 ET382342.26
01:32 ET70042.24
01:33 ET50042.205
01:35 ET143742.085
01:37 ET143942.05
01:39 ET10042.035
01:42 ET200041.93
01:44 ET10042.01
01:46 ET20041.915
01:48 ET92042.02
01:50 ET90042.015
01:51 ET40041.86
01:53 ET30041.86
01:55 ET20041.86
01:57 ET50041.88
02:00 ET12541.88
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGPCR
Structure Therapeutics Inc
2.4B
-18.7x
---
United StatesCGON
CG Oncology Inc
2.4B
-31.2x
---
United StatesIBRX
Immunitybio Inc
2.4B
-3.7x
---
United StatesEWTX
Edgewise Therapeutics Inc
2.5B
-18.1x
---
United StatesVRNA
Verona Pharma PLC
2.5B
-20.8x
---
United StatesSWTX
SpringWorks Therapeutics Inc
2.4B
-7.4x
---
As of 2024-10-04

Company Information

Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is developing GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefit. It is developing ANPA-0073, an investigational oral small molecule APJR agonist, for the treatment of idiopathic pulmonary fibrosis (IPF). It is evaluating its LPA1R program, LTSE-2578 for IPF and progressive pulmonary fibrosis.

Contact Information

Headquarters
611 Gateway Blvd Suite 223SOUTH SAN FRANCISCO, CA, United States 94080
Phone
---
Fax
---

Executives

Independent Chairman of the Board
Daniel Welch
Chief Executive Officer, Director
Raymond Stevens
Chief Financial Officer
Jun Yoon
Chief Technology Officer
Yingli Ma
Chief Scientific Officer
Xichen Lin

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$2.4B
Revenue (TTM)
$0.00
Shares Outstanding
57.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.24
Book Value
$9.76
P/E Ratio
-18.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.